Is ABBV a Buy? What to Consider in 2026
Short answer
The bull case for AbbVie (ABBV) rests on Skyrizi and Rinvoq replacing Humira faster than expected: Skyrizi and Rinvoq generated a combined $25.9 billion in 2025, exceeding AbbVie's own 2027 combined guidance by roughly $500 million two full years ahead of schedule. Revenue (FY 2025, reported) is ~$61.2 billion. If you believe that thesis holds, the real questions become position sizing and overlap, not timing. The main risk to that view: The single largest structural risk is portfolio concentration: Skyrizi and Rinvoq together account for a rapidly growing share of total revenue, meaning any clinical setback, competitive entry in atopic dermatitis (where Regeneron's Dupixent holds a strong position), or government-mandated price cut under the Inflation Reduction Act could materially impair the growth outlook. Whether ABBV is a buy comes down to whether you believe the thesis. This is informational, not a recommendation, and Walnut is not an investment adviser.
AbbVie is a North Chicago-based research-driven biopharmaceutical company spun off from Abbott Laboratories in 2013. It focuses on discovering and commercializing medicines for immunology, oncology, neuroscience, and aesthetics. Its immunology franchise anchors the business: historically through Humira (adalimumab), and increasingly through Skyrizi (risankizumab) and Rinvoq (upadacitinib), which treat conditions such as plaque psoriasis, Crohn's disease, rheumatoid arthritis, and ulcerative colitis. Oncology contributes through Imbruvica (developed in collaboration with Johnson and Johnson) and Venclexta (in collaboration with Roche), while the 2020 acquisition of Allergan added Botox Therapeutic, Vraylar, and the aesthetics portfolio including Botox Cosmetic and Juvederm. Revenue is generated by selling branded pharmaceuticals at negotiated prices to wholesale distributors, specialty pharmacies, and health systems across more than 175 countries. AbbVie was led by founder Richard Gonzalez from its 2013 spin-off until late 2023, when Robert A. Michael became chief executive officer. Under Gonzalez, AbbVie transformed from a Humira-dependent entity into a diversified biopharma by acquiring Pharmacyclics (2015), Stemcentrx (2016), and Allergan (2020) for a combined investment exceeding $80 billion. Michael took the helm as the Humira loss-of-exclusivity cycle was cresting and has since overseen record net revenues of $61.16 billion in full-year 2025, a figure that the company says surpassed the previous Humira-era revenue peak in only the second year following U.S. Humira biosimilar entry. AbbVie employs roughly 57,000 people globally and trades on the New York Stock Exchange.
What's the case for buying ABBV?
Skyrizi and Rinvoq replacing Humira faster than expected
Skyrizi and Rinvoq generated a combined $25.9 billion in 2025, exceeding AbbVie's own 2027 combined guidance by roughly $500 million two full years ahead of schedule. Forecasts project this duo reaching approximately $50 billion by 2030, powered by label expansions in Crohn's disease, atopic dermatitis, and other inflammatory conditions. The subcutaneous Skyrizi approval in Crohn's, confirmed through the Phase 3 AFFIRM trial, adds a formidable commercial moat in one of the highest-value gastroenterology markets.
Neuroscience becoming a meaningful second growth engine
AbbVie's neuroscience portfolio grew roughly 19.6 percent in 2025 to $10.767 billion, driven by Botox Therapeutic, Vraylar (bipolar depression and schizophrenia), and migraine drugs Ubrelvy and Qulipta. Management has flagged its Parkinson's treatment Vyalev as a potential blockbuster and is targeting a combined migraine franchise of $5 billion or more at peak. This diversification gives AbbVie a revenue base less tied to a single therapeutic class than most peers of similar size.
Prolific free cash flow funds both a growing dividend and M and A optionality
AbbVie generated more than $17.8 billion in free cash flow in 2025, and management guided to approximately $18.5 billion for 2026. That cash engine supports a dividend that has grown for 12 consecutive years at a 12.5 percent compound annual rate since 2013, with a current annualized payout of roughly $6.92 per share. Surplus capital is being directed at pipeline bolt-ons, with more than $5 billion deployed in business development in 2025 alone across platforms in obesity, neuroscience, oncology, and next-generation immunology.
2026 guidance points to durable double-digit earnings growth
Management guided 2026 full-year adjusted EPS to $14.37 to $14.57, representing meaningful acceleration from the $10.00 adjusted EPS reported for 2025, with total net revenue guided to approximately $67 billion, a 9.5 percent increase. The adjusted operating margin is expected to expand, and a PEG ratio near 0.91 (forward basis) suggests the market may be pricing in slower growth than management guidance implies. Analyst consensus forecasts continued EPS growth through 2029 as Skyrizi, Rinvoq, and neuroscience assets compound.
What are the risks to ABBV?
The single largest structural risk is portfolio concentration: Skyrizi and Rinvoq together account for a rapidly growing share of total revenue, meaning any clinical setback, competitive entry in atopic dermatitis (where Regeneron's Dupixent holds a strong position), or government-mandated price cut under the Inflation Reduction Act could materially impair the growth outlook. AbbVie also carries a heavy debt load, reported at roughly $72.9 billion as of the most recent period, a legacy of the Allergan acquisition, constraining financial flexibility if credit markets tighten or a major pipeline bet fails. Ongoing integration of large acquisitions such as the pending Apogee Therapeutics deal introduces execution risk, and the aesthetics segment (Botox Cosmetic, Juvederm) has shown sensitivity to consumer spending cycles and competition from emerging aesthetic treatments.
How is ABBV valued? (as of 2026-06-27)
- Revenue (FY 2025, reported): ~$61.2 billion
- Adjusted Diluted EPS (FY 2025): $10.00
- GAAP Diluted EPS (FY 2025): $2.36
- Forward P/E (consensus FY 2026 estimate): ~15.7x
- EV/EBITDA (TTM): ~15.9x
- Dividend Yield (TTM, as of late June 2026): ~3.0%
- Free Cash Flow (FY 2025): ~$17.8 billion
- Market Capitalization (approx.): ~$403 billion
The large gap between the trailing GAAP P/E (elevated, reflecting non-cash acquired IPR and D charges on recent deals) and the forward P/E of roughly 15.7x illustrates why analysts and management prefer adjusted metrics: large upfront licensing and milestone payments depress reported earnings without reducing cash generation. On a free cash flow basis, AbbVie trades at a more modest multiple, and the PEG ratio near 0.91 suggests the consensus earnings growth rate is tracking faster than the headline valuation implies. The 2026 revenue guidance of roughly $67 billion and adjusted EPS of $14.37 to $14.57 would, if achieved, represent meaningful upward re-rating from 2025 reported figures.
How do you decide if ABBV is a buy?
Rather than asking whether ABBV is a buy in the abstract, it tends to help to answer four questions:
- Thesis: do you believe the case above, and is it still true today?
- Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
- Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
- Overlap: check whether you already hold ABBV indirectly through an index or sector ETF before adding more.
For the full picture, see the ABBV stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about ABBV against your real portfolio and see your actual exposure before deciding.
The bottom line on ABBV
The bottom line: AbbVie's story right now is Skyrizi and Rinvoq replacing Humira faster than expected, with revenue (fy 2025, reported) at ~$61.2 billion. If you believe that narrative continues, the call is about sizing ABBV sensibly and checking overlap with what you own; if you doubt it (the risk: the single largest structural risk is portfolio concentration: Skyrizi and Rinvoq together account for a rapidly growing share of total revenue, meaning any clinical setback, competitive entry in atopic dermatitis (where Regeneron's Dupixent holds a strong position), or government-mandated price cut under the Inflation Reduction Act could materially impair the growth outlook.), it is not for you. Decide from the thesis, not the ticker. Walnut is not an investment adviser.
Build a basket around ABBV with Walnut
Use AbbVie as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
Is ABBV a good stock to buy right now?
+
The case for AbbVie right now is Skyrizi and Rinvoq replacing Humira faster than expected, with revenue (fy 2025, reported) at ~$61.2 billion. If you believe that thesis holds, ABBV is a way to own it and the real questions are sizing and overlap, not timing; the main risk to that view is the single largest structural risk is portfolio concentration: Skyrizi and Rinvoq together account for a rapidly growing share of total revenue, meaning any clinical setback, competitive entry in atopic dermatitis (where Regeneron's Dupixent holds a strong position), or government-mandated price cut under the Inflation Reduction Act could materially impair the growth outlook. So it comes down to whether you believe the thesis. Walnut is not an investment adviser and this is not a recommendation.
What does AbbVie do?
+
AbbVie is a North Chicago-based research-driven biopharmaceutical company spun off from Abbott Laboratories in 2013.
What are the main risks of ABBV?
+
The single largest structural risk is portfolio concentration: Skyrizi and Rinvoq together account for a rapidly growing share of total revenue, meaning any clinical setback, competitive entry in atopic dermatitis (where Regeneron's Dupixent holds a strong position), or government-mandated price cut under the Inflation Reduction Act could materially impair the growth outlook. AbbVie also carries a heavy debt load, reported at roughly $72.9 billion as of the most recent period, a legacy of the Allergan acquisition, constraining financial flexibility if credit markets tighten or a major pipeline bet fails. Ongoing integration of large acquisitions such as the pending Apogee Therapeutics deal introduces execution risk, and the aesthetics segment (Botox Cosmetic, Juvederm) has shown sensitivity to consumer spending cycles and competition from emerging aesthetic treatments.
What does AbbVie do?
+
AbbVie is a research-based biopharmaceutical company that discovers and sells medicines for immunology (Skyrizi, Rinvoq, Humira), oncology (Imbruvica, Venclexta), neuroscience (Vraylar, Botox Therapeutic, Ubrelvy), and aesthetics (Botox Cosmetic, Juvederm). It operates globally with roughly 57,000 employees and reported full-year 2025 revenue of approximately $61.2 billion.
Is ABBV a good stock to buy right now?
+
Whether ABBV suits a portfolio depends on an investor's goals, time horizon, and existing holdings. The forward P/E near 15.7x and a PEG ratio below 1.0 look relatively modest for a company guiding to double-digit EPS growth in 2026. Key uncertainties include drug pricing policy, portfolio concentration in Skyrizi and Rinvoq, and a large debt load. No single answer fits all investors.
Does ABBV pay a dividend?
+
Yes. AbbVie pays a quarterly cash dividend and has raised it for 12 consecutive years. The most recent quarterly dividend is $1.73 per share, for a current annualized payout of roughly $6.92 per share and a yield near 3 percent as of late June 2026. The dividend has grown at roughly 12.5 percent per year since the 2013 Abbott spin-off.
Is ABBV overvalued?
+
Valuation depends on which metric is used. The trailing GAAP P/E appears elevated because large non-cash acquisition charges depress reported earnings. On a forward adjusted-EPS basis the multiple is roughly 15.7x, and the PEG ratio near 0.91 implies the growth rate is fast enough to make that multiple look reasonable by historical pharma standards. Bears would note the high absolute debt level and concentration risk.
Walnut is informational and is not an investment adviser. This page is educational and not a recommendation to buy or sell ABBV; figures are approximate and dated, and your own situation, time horizon, and risk tolerance should drive any decision. Verify current data before investing.